The Effects of Lidocaine and Esmolol on Attenuation of Hemodynamic Response to Orotracheal Intubation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-01

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study aims to compare the hemodynamic response during laryngoscopy and orotracheal intubation using continuous infusion of lidocaine and esmolol in patients undergoing general anesthesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation

NCT04264286

Beta Blocker Hemodynamic Instability

UNKNOWN PHASE4

The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation

NCT02359370

Intubation Complication Cardiovascular Morbidity

COMPLETED PHASE4

Intravenous Lidocaine to Supress of Cough Reflex During Anesthesia Emergence

NCT03805282

Cough

UNKNOWN PHASE3

The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study

NCT07089173

Hemodynamics

RECRUITING NA

Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity

NCT00440102

Intubation; Difficult

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Esmolol is a selective beta-blocker of fast action that antagonizes beta-1 adrenergic receptors. Venous lidocaine is the agent most used to attenuate the hemodynamic response to laryngoscopy and intubation, in addition to cough reflex.

Objective: To compare the hemodynamic response during laryngoscopy and orotracheal intubation using continuous infusion of lidocaine and esmolol.

Methods: Randomized, double masked clinical trial aims to compare the effect of esmolol and lidocaine on orotracheal intubation. All patients will receive balanced general anesthesia. One group (EG) will receive bolus esmolol of 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min. The lidocaine (LG) group will receive lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.

Data on hemodynamic changes, reaction to laryngoscopy, conditions at intubation and adverse events will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodynamic Instability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Esmolol Group

Patients will receive esmolol during induction of anesthesia

Group Type ACTIVE_COMPARATOR

Esmolol

Intervention Type DRUG

Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.

Lidocaine

Intervention Type DRUG

Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.

Lidocaine Group

Patients will receive lidocaine during induction of anesthesia

Group Type ACTIVE_COMPARATOR

Esmolol

Intervention Type DRUG

Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.

Lidocaine

Intervention Type DRUG

Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esmolol

Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.

Intervention Type DRUG

Lidocaine

Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Beta blocker Local anesthetic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 18 and 70 years
* Physical State 1, 2 or 3 of the American Society of Anesthesiology (ASA)
* Electively or urgently scheduled for surgery requiring general anesthesia, with programming of orotracheal intubation via direct laryngoscopy at the Base Hospital of the Federal District.

Exclusion Criteria

* Patients younger than 18 and over 70 years of age
* Patients with contraindications or history of hypersensitivity to the drugs involved in the study
* Patients with coronary ischemic disease
* Patients with atrioventricular block at any grade
* Patients with diagnosed cardiac arrhythmias
* Patients with heart failure
* Patients who are beta-blockers or calcium channel blockers
* Patients with renal insufficiency of any kind
* Patients with difficulty predicting orotracheal intubation
* Patients with BMI ≥ 35 kg / m²
* Patients who underwent neuroaxis block before anesthetic induction
* Patients who refuse to participate in the study after submitting the informed consent form
* Patients requiring two or more attempts of laryngoscopy for positioning of the orotracheal tube
* Patients with asthma
* Any other condition that, in the opinion of the researcher, may pose a risk to the patient or interfere with the objectives of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes